Durable responses with PD-1 inhibition in lung and kidney cancer and the ongoing search for predictive biomarkers

Journal of Clinical Oncology

Volumn 33, Issue 18, 2015, Pages 1993-1994

  Awad, Mark M ^a   Hammerman, Peter S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; EVEROLIMUS; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LUNG CANCER; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; FEMALE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE;

EID: 84937565561     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.4172     Document Type: Editorial

References (21)

1. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
2. Kanesvaran R, Tan MH: Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 13:3, 2014
3. Schutz FA, Je Y, Richards CJ, et al: Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871-877, 2012
4. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
5. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
6. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
7. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
8. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
9. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015
10. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004-2012, 2015
11. McDermott DF, Drake CG, Sznol M, et al: Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33:2013-2020, 2015
12. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
13. Hellmann MD, Creelan BC, Woo K, et al: Smoking history and response to nivolumab in patients with advanced NSCLCS. Ann Oncol 25:iv429, 2014 (suppl 4; abstr 1229PD)
14. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-218, 2013
15. Snyder A, Makarov V, Merghoub T, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199, 2014
16. Garon EB, Gandhi L, Rizvi N, et al: Antitumor activity of pembrolizumab (PEMBRO; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol 25:v1-v41, 2014 (suppl 4; abstr LBA43)
17. Patel SP, Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther [epub ahead of print on February 18, 2015]
18. Soria J-C, Gettinger S, Gordon M, et al: Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer (NSCLC) patients (pts) in a phase I study of MPDL3280A. Ann Oncol 25:iv465, 2014 (suppl 4; abstr 1322P)
19. Akbay EA, Koyama S, Carretero J, et al: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3:1355-1363, 2013
20. Atefi M, Avramis E, Lassen A, et al: Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20:3446-3457, 2014
21. Choueiri TK, Fishman MN, Escudier BJ, et al: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 32:326s, 2014 (suppl 15; abstr 5012)